Do older men benefit from curative therapy of localized prostate cancer?

Journal of Clinical Oncology

Volumn 21, Issue 17, 2003, Pages 3318-3327

  Alibhai, Shabbir M H ^a   Naglie, Gary ^a   Nam, Robert ^a   Trachtenberg, John ^a   Krahn, Murray D ^a  

^a TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMORBIDITY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; GERIATRIC PATIENT; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; WATCHFUL WAITING; AGED; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROBABILITY; PROSTATE TUMOR; RADIOTHERAPY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COMORBIDITY; DECISION SUPPORT TECHNIQUES; HUMANS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 0141465122     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.034     Document Type: Article

References (98)

1. Holmberg L, Bill-Axelson A, Helgesen F, et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781-789, 2002
2. Middleton RG, Thompson IM, Austenfeld MS, et al: Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer: The American Urological Association. J Urol 154:2144-2148, 1995
3. Aus G, Abbou CC, Pacik D, et al: EAU guidelines on prostate cancer. Eur Urol 40:97-101, 2001
4. Albertsen PC, Fryback DG, Storer BE, et al: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626-631, 1995
5. Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330:242-248, 1994
6. Vicini FA, Horwitz EM, Gonzalez J, et al: Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J Urol 158:319-325, 1997
7. Vicini FA, Horwitz EM, Kini VR, et al: Treatment options for localized prostate cancer based on pretreatment serum prostate-specific antigen levels and biochemical control: A comprehensive review of the literature. Int J Radiat Oncol Biol Phys 40:1101-1110, 1998
8. Menon M, Parulkar BG, Baker S: Should we treat localized prostate cancer? An opinion. Urology 46:607-616, 1995
9. Albertsen PC, Hanley JA, Gleason DF, et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975-980, 1998
10. Walsh PC: The natural history of localized prostate cancer: A guide to therapy, in Walsh PC, Retik AB, Vaughan ED, et al (eds): Campbell's Urology (ed 7). Philadelphia, PA, W.B. Saunders, 1998, pp 2539-2546
11. Manton KG, Vaupel JW: Survival after the age of 80 in the United States, Sweden, France, England, and Japan. N Engl J Med 333:1232-1235, 1995
12. Nam RK, Jewett MAS, Krahn MD: Prostate cancer: 2. Natural history. Can Med Assoc J 159:685-691, 1998
13. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451, 1997
14. Kattan MW, Zelefsky MJ, Kupelian PA, et al: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352-3359, 2000
15. Alibhai SMH, Krahn MD, Cohen MM, et al: Older patients receive less aggressive treatment for clinically localized prostate cancer. Clin Invest Med 23:332, 2000 (abstr)
16. Potosky AL, Merrill RM, Riley GF, et al: Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. Health Serv Res 34:525-546, 1999
17. Yan Y, Carvalhal GF, Catalona WJ, et al: Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 88:1122-1130, 2000
18. Bubolz T, Wasson JH, Lu-Yao G, et al: Treatments for prostate cancer in older men: 1984-1997. Urology 58:977-982, 2001
19. Bennett CL, Greenfield S, Aronow H, et al: Patterns of care related to age of men with prostate cancer. Cancer 67:2633-2641, 1991
20. Fleming C, Wasson JH, Albertsen PC, et al: A decision analysis of alternative treatment strategies for clinically localized prostate cancer: Prostate Patient Outcomes Research Team. JAMA 269:2650-2658, 1993
21. Kattan MW, Cowen ME, Miles BJ: A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 12:299-305, 1997
22. Walsh PC: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. J Urol 150:1330-1332, 1993
23. Leibel SA, Zelefsky MJ, Kutcher GJ, et al: The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 21:580-597, 1994
24. Hanks GE, Hanlon AL, Schultheiss TE, et al: Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501-510, 1998
25. Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491-500, 1998
26. Trachtenberg J, Crook J, Tannock IF: Prostate cancer: 11. Alternative approaches and the future of treatment. Can Med Assoc J 160:528-534, 1999
27. Cowen ME, Chartrand M, Weitzel WF: A Markov model of the natural history of prostate cancer. J Clin Epidemiol 47:3-21, 1994
28. Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58-64, 1974
29. Gleave ME, Bruchovsky N, Moore MJ, et al: Prostate cancer: 9. Treatment of advanced disease. Can Med Assoc J 160:225-232, 1999
30. Statistics Canada: Life tables, Canada and Provinces. Health Rep 2:17, 1990 (Suppl 13)
31. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
32. Leibman BD, Dillioglugil O, Wheeler TM, et al: Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 76:2530-2534, 1995
33. Lu-Yao GL, Yao S-L: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349:906-910, 1997
34. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 355:1491-1498, 2000
35. Gerber GS, Thisted RA, Scardino PT, et al: Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 276:615-619, 1996
36. Shipley WU, Thames HD, Sandler HM, et al: Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 281:1598-1604, 1999
37. Lu-Yao GL, Albertsen P, Warren J, et al: Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy: A population-based study. Urology 54:301-307, 1999
38. Lu-Yao GL, McLerran D, Wasson J, et al: An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes: The Prostate Patient Outcomes Research Team. JAMA 269:2633-2636, 1993
39. Stanford JL, Feng Z, Hamilton AS, et al: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA 283:354-360, 2000
40. Davidson PJ, van den Ouden D, Schroeder FH: Radical prostatectomy: Prospective assessment of mortality and morbidity. Eur Urol 29:168-173, 1996
41. Shipley WU, Zietman AL, Hanks GE, et al: Treatment related sequelae following external beam radiation for prostate cancer: A review with an update in patients with stages T1 and T2 tumor. J Urol 152:1799-1805, 1994
42. Wasson JH, Cushman CC, Bruskewitz RC, et al: A structured literature review of treatment for localized prostate cancer: Prostate Disease Patient Outcome Research Team. Arch Fam Med 2:487-493, 1993
43. Talcott JA, Rieker P, Clark JA, et al: Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study. J Clin Oncol 16:275-283, 1998
44. Borghede G, Hedelin H: Radiotherapy of localised prostate cancer: Analysis of late treatment complications-A prospective study. Radiother Oncol 43:139-146, 1997
45. Caffo O, Fellin G, Graffer U, et al: Assessment of quality of life after radical radiotherapy for prostate cancer. Br J Urol 78:557-563, 1996
46. Crook J, Esche B, Futter N: Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: The patient's perspective. Urology 47:387-394, 1996
47. Duncan W, Warde P, Catton CN, et al: Carcinoma of the prostate: Results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys 26:203-210, 1993
48. El-Galley RES, Howard GCW, Hawkyard S, et al: Radical radiotherapy for localized adenocarcinoma of the prostate: A report of 191 cases. Br J Urol 75:38-43, 1994
49. Lim AJ, Brandon AH, Fiedler J, et al: Quality of life: Radical prostatectomy versus radiation therapy for prostate cancer. J Urol 154:1420-1425, 1995
50. Mameghan H, Fisher R, Watt WH, et al: Results of radiotherapy for localised prostatic carcinoma treated at the Prince of Wales Hospital, Sydney. Med J Aust 154:317-326, 1991
51. McCammon KA, Kolm P, Main B, et al: Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology 54:509-516, 1999
52. Widmark A, Fransson P, Tavelin B: Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 74:2520-2532, 1994
53. Lawton CA, Won M, Pilepich MV, et al: Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21:935-939, 1991
54. Arcangeli G, Micheli A, Pansadoro V, et al: Definitive radiation therapy for localized prostatic adenocarcinoma. Int J Radiat Oncol Biol Phys 20:439-446, 1991
55. Aygun C, Blum J, Stark L: Long-term clinical and prostate-specific antigen follow-up in 500 patients treated with radiation therapy for localized prostate cancer. Maryland Med J 44:363-368, 1995
56. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, et al: Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 38:311-317, 1997
57. Shrader-Bogen CL, Kjellberg JL, McPherson CP, et al: Quality of life and treatment outcomes. Cancer 79:1977-1986, 1997
58. Diokno AC, Brown MB, Herzog AR: Sexual function in the elderly. Arch Intern Med 150:197-200, 1990
59. Maggi S, Minicuci N, Langlois J, et al: Prevalence rate of urinary incontinence in community-dwelling elderly individuals: The Veneto study. J Gerontol A Biol Sci Med Sci 56:M14-M18, 2001
60. Krahn MD, Ritvo P, Naglie G, et al: Construction of PORPUS (Patient Oriented Prostate Utility Scale): An Empirically Derived Multiattribute Health State Classification System for Prostate Cancer. J Clin Epidemiol 53:920-930, 2000
61. Cantor SB, Volk RJ, Krahn MD, et al: Couples' preferences for prostate cancer health states. Med Decis Making 19:537, 1999 (abstr)
62. Volk RJ, Cantor SB, Spann SJ, et al: Preferences of husbands and wives for prostate cancer screening. Arch Fam Med 6:72-76, 1997
63. Bennett CL, Chapman G, Elstein AS, et al: A comparison of perspectives on prostate cancer: Analysis of utility assessments of patients and physicians. Eur Urol 32:86-88, 1997
64. Cowen ME, Cahill D, Kattan MW, et al: The value or utility of prostate cancer states. J Urol 155:376A, 1996 (abstr 261, suppl).
65. Nease RF Jr, Kneeland T, O'Connor GT, et al: Variation in patient utilities for outcomes of the management of chronic stable angina: Implications for clinical practice guidelines-Ischemic Heart Disease Patient Outcomes Research Team JAMA 273:1185-1190, 1995
66. Naglie G, Tansey C, Krahn M: Seniors' preferences for chronic health states: Utility assessments of heart disease, stroke, and dementia. Med Decis Making 17:521, 1997 (abstr)
67. Hanks GE, Hanlon AL, Pinover WH, et al: Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 5:152-158, 1999
68. Zelefsky MJ, Fuks Z, Hunt M, et al: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876-881, 2001
69. D'Amico AV, Schultz D, Loffredo M, et al: Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 284:1280-1283, 2000
70. Fiveash JB, Hanks G, Roach M, et al: 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: A multi-institutional review. Int J Radiat Oncol Biol Phys 47:335-342, 2000
71. Kuban DA, El-Mahdi AM, Schellhammer PF: Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 32:307-316, 1995
72. Krahn M, Ritvo P, Irvine J, et al: Patient and community preferences for outcomes in prostate cancer: Implications for clinical policy. Med Care 41:153-164, 2003
73. Litwin MS, Hays RD, Fink A, et al: The UCLA Prostate Cancer Index: Development, reliability, and validity of a health-related quality of life measure. Med Care 36:1002-1012, 1998
74. Beck JR, Scardino PT: How useful are models of natural history in clinical decision making and clinical research? J Clin Epidemiol 47:1-2, 1994
75. Cowen ME, Miles BJ, Cahill DF, et al: The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making 18:376-380, 1998
76. Krumins PE, Fihn SD, Kent DL: Symptom severity and patients' values in the decision to perform a transurethral resection of the prostate. Med Decis Making 8:1-8, 1988
77. Krahn MD, Mahoney JE, Eckman MH, et al: Screening for prostate cancer: A decision analytic view. JAMA 272:773-780, 1994
78. Cantor SB, Spann SJ, Volk RJ, et al: Prostate cancer screening: A decision analysis. J Fam Pract 41:33-41, 1995
79. Yoshimura N, Takami N, Ogawa O, et al: Decision analysis for treatment of early stage prostate cancer. Jpn J Cancer Res 89:681-689, 1998
80. Goldenberg SL, Ramsey EW, Jewett MAS: Prostate cancer: 6. Surgical treatment of localized disease. Can Med Assoc J 159:1265-1271, 1998
81. Warde P, Catton C, Gospodarowicz MK: Prostate cancer: 7. Radiation therapy for localized disease. Can Med Assoc J 159:1381-1388, 1998
82. Albertsen PC, Fryback DG, Storer BE, et al: The impact of comorbidity on life expectancy among men with localized prostate cancer. J Urol 156:127-132, 1996
83. Greenfield S, Apolone G, McNeil BJ, et al: The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Med Care 31:141-154, 1993
84. Detsky AS, Abrams HB, Forbath N, et al: Cardiac assessment for patients undergoing noncardiac surgery: A multifactorial clinical risk index. Arch Intern Med 146:2131-2134, 1986
85. Minino AM, Smith BL: Deaths: Preliminary data for 2000. Natl Vital Stat Rep 49:1-40, 2001
86. Klima MP, Povysil C, Teasdale TA: Causes of death in geriatric patients: A cross-cultural study. J Gerontol A Biol Sci Med Sci 52: M247-M253, 1997
87. Naimark D, Naglie G, Detsky AS: The meaning of life expectancy: What is clinically significant gain? J Gen Intern Med 9:702-707, 1994
88. Savage P, Bates C, Abel P, et al: British urological surgery practice: 1. Prostate cancer. Br J Urol 79:749-755, 1997
89. Krahn MD, Bremner KE, Asaria J, et al: The ten-year rule revisited: Accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology 60:258-263, 2002
90. Mazur DJ, Hickam DH: Patient preferences for management of localized prostate cancer. West J Med 165:26-30, 1996
91. Singer PA, Tasch ES, Stocking C, et al: Sex or survival: Trade-offs between quality and quantity of life. J Clin Oncol 9:328-334, 1991
92. Walsh PC, Donker PJ: Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 128:492-497, 1982
93. Wilt TJ, Brawer MK: The Prostate Cancer Intervention Versus Observation Trial: A randomization trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 152:1910-1914, 1994
94. Zelefsky MJ, Wallner KE, Ling CC, et al: Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 17:517-522, 1999
95. Green GA, Hanlon AL, Al-Saleem T, et al: A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer 83:971-976, 1998
96. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
97. Stamey TA, McNeal JE, Yemoto CM, et al: Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395-1400, 1999
98. Yang XJ, Lecksell K, Potter SR, et al: Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy. Urology 54:528-532, 1999